The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
What are the current treatment options for intermediate/higher-risk patients with myelofibrosis?
Featured:
John MascarenhasDuring the International Academy for Clinical Hematology (IACH) 2023 Congress, the MPN Hub was pleased to speak with John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, What are the current treatment options for intermediate/higher-risk patients with myelofibrosis?
Mascarenhas begins by outlining the goals of treatment, focusing on managing anemia in patients with a low platelet count. He then explores the option of bone marrow transplantation and discusses treatment options for patients with a high platelet count. Mascarenhas concludes by delving into emerging treatment options and potential combination therapies.
What are the current treatment options for intermediate/higher risk patients with MF?